A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant non–small cell lung cancer (NSCLC).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Alexander I. Spira, David R. Spigel, D. Ross Camidge, Adrianus De Langen, Tae Min Kim, Koichi Goto, Yasir Y Elamin, Elaine Shum, Karen L. Reckamp, Julia K Rotow, Sarah B. Goldberg, Shirish M. Gadgeel, Ticiana Leal, Faris Albayya, Sarah Fitzpatrick, Melinda Louie-Gao, Jagan Parepally, Alena Zalutskaya, Helena Alexandra Yu
Institutions: Virginia Cancer Specialists, Sarah Cannon, Tennessee Oncology, University of Colorado Cancer Center, The Netherlands Cancer Institute, Seoul National University Hospital, National Cancer Center Hospital East, The University of Texas MD Anderson Cancer Center, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, Cedars-Sinai Medical Center, Dana-Farber Cancer Institute, Yale University, Henry Ford Health, Henry Ford Hospital, Winship Cancer Institute, Blueprint Medicines (United States), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281728024